NCCN Guidelines® Insights: Neuroendocrine and adrenal tumors, version 2.2018: Featured updates to the NCCN Guidelines Journal Article


Authors: Shah, M. H.; Goldner, W. S.; Halfdanarson, T. R.; Bergsland, E.; Berlin, J. D.; Halperin, D.; Chan, J.; Kulke, M. H.; Benson, A. B. 3rd; Blaszkowsky, L. S.; Eads, J.; Engstrom, P. F.; Fanta, P.; Giordano, T.; He, J.; Heslin, M. J.; Kalemkerian, G. P.; Kandeel, F.; Khan, S. A.; Kidwai, W. Z.; Kunz, P. L.; Kuvshinoff, B. W. 2nd; Lieu, C.; Pillarisetty, V. G.; Saltz, L.; Sosa, J. A.; Strosberg, J. R.; Sussman, C. A.; Trikalinos, N. A.; Uboha, N. A.; Whisenant, J.; Wong, T.; Yao, J. C.; Burns, J. L.; Ogba, N.; Zuccarino-Catania, G.
Article Title: NCCN Guidelines® Insights: Neuroendocrine and adrenal tumors, version 2.2018: Featured updates to the NCCN Guidelines
Abstract: The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 6
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-06-01
Start Page: 693
End Page: 702
Language: English
DOI: 10.6004/jnccn.2018.0056
PROVIDER: scopus
PUBMED: 29891520
DOI/URL:
Notes: Review -- Export Date: 1 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leonard B Saltz
    790 Saltz
Related MSK Work